Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pneumococcal Pneumonia in Hospitalized Children: 2017-2023.

Pediatrics·2026
Same author

BinaxNOW <i>Streptococcus pneumoniae</i> Antigen Assay in Pleural Fluid for Detection of <i>S pneumoniae</i> in Children With Empyema.

Clinical pediatrics·2026
Same author

Healthcare providers' preferences for pediatric pneumococcal vaccination recommendations in the United States.

Expert review of vaccines·2025
Same author

Invasive Pneumococcal Disease at Eight Children's Hospitals in the United States, 2018-2023.

The Pediatric infectious disease journal·2025
Same author

SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.

PloS one·2025
Same author

Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance status.

Frontiers in public health·2025
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Prevenar experience.

Adriano Arguedas1, Carolina Soley, Arturo Abdelnour

  • 1Instituto de Atención Pediátrica, San José, Costa Rica. aarguedas@iped.net

Vaccine
|September 8, 2011
PubMed
Summary
This summary is machine-generated.

The heptavalent conjugated pneumococcal vaccine (PCV7) significantly reduced invasive pneumococcal disease and related infections in young children. This vaccine also demonstrated a herd effect, protecting unvaccinated individuals and reducing antimicrobial resistance.

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Related Experiment Videos

Last Updated: May 29, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Vaccinology

Background:

  • Streptococcus pneumoniae causes significant morbidity and mortality globally, particularly in children under 5 and adults over 65.
  • It is the leading vaccine-preventable cause of death in young children, as recognized by the WHO.
  • The first heptavalent conjugated pneumococcal vaccine (PCV7) was introduced in 2000, offering protection in children under 2, unlike older polysaccharide vaccines.

Purpose of the Study:

  • To evaluate the impact of the heptavalent conjugated pneumococcal vaccine (PCV7) on invasive pneumococcal disease (IPD) and other related infections.
  • To assess the effectiveness of PCV7 in reducing S. pneumoniae infections across different age groups and vaccination regimens.

Main Methods:

  • Analysis of efficacy data from initial studies of PCV7 in the United States.
  • Review of post-introduction data on PCV7 use in national immunization programs over 11 years.
  • Examination of infection rates, medical visits, and antimicrobial resistance patterns before and after PCV7 implementation.

Main Results:

  • PCV7 demonstrated 97.4% efficacy against IPD caused by its target serotypes.
  • Introduction of PCV7 led to significant reductions in IPD, non-bacteremic pneumonia, otitis media, and antimicrobial resistance in children under 5.
  • A herd effect was observed, with reduced S. pneumoniae infections in unvaccinated children and adults, including the elderly.
  • Vaccine effectiveness was confirmed with both standard 4-dose and reduced-dose regimens.

Conclusions:

  • The heptavalent conjugated pneumococcal vaccine (PCV7) has been highly effective in controlling pneumococcal infections in young children.
  • PCV7 implementation has broader public health benefits, including protection of unvaccinated populations and reduction of antibiotic resistance.
  • The vaccine's effectiveness is robust across different dosing strategies, supporting its widespread use.